Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
• Pexa-Vec selectively targets tumor tissue after intravenous (i. v.) administration and stimulates the adaptive and innate anti-tumor immune response
• Pexa-Vec induces expression of PD-L1 and PD-1 pathways reinforcing the rationale for combination with immune checkpoint inhibitors
• Of the four evaluable patients with liver metastases, one showed complete tumor pathological response at the time of surgery
• Data support ongoing development of Transgene’s Vaccinia virus-based oncolytics (Pexa-Vec, TG6002 drug candidates and Invir.IOTM preclinical candidates)
Strasbourg, France, and Leeds, United Kingdom, June 4, 2018, 5:45 p.m. CET
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, and University of Leeds, announce that new clinical data obtained with Pexa-Vec further demonstrate anti-tumor activity after intravenous (i. v.) infusion. These data were presented by Dr. Alan Anthoney (University of Leeds) in a poster presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting, June 4, in Chicago.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer